⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
10,726
Total Claims
$4.5M
Drug Cost
926
Beneficiaries
$4,898
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+25%
Cost per patient vs peers
$4,898 vs $3,933 avg
+6%
Brand preference vs peers
54.2% vs 51.2% avg
Brand vs Generic
46% generic
Brand: 5,418 claims · $4.4M
Generic: 4,573 claims · $104K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 891 | $718K |
| Insulin Aspart | 497 | $541K |
| Dulaglutide | 298 | $359K |
| Semaglutide | 255 | $296K |
| Sitagliptin Phosphate | 318 | $263K |
| Insulin Aspart | 167 | $183K |
| Dapagliflozin Propanediol | 183 | $148K |
| Insulin Lispro | 93 | $133K |
| Tirzepatide | 106 | $132K |
| Insulin Glargine,hum.Rec.Anlog | 229 | $130K |
| Insulin Glargine/Lixisenatide | 112 | $124K |
| Semaglutide | 112 | $119K |
| Insulin Degludec | 176 | $117K |
| Insulin Glargine,hum.Rec.Anlog | 101 | $78K |
| Insulin Lispro | 75 | $77K |
Prescribing Profile
Patient Profile
70
Avg Age
64%
Female
2.10
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About